Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Healthy

Treatments: Drug: fesoterodine fumarate; Drug: solifenacin; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00832650

A0221057

Details and patient eligibility

About

To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.

Enrollment: 60 patients

Sex: Female

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy female subjects

Exclusion criteria

• Evidence or history of clinically significant findings at screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 3 patient groups, including a placebo group

Fesoterodine

Experimental group

Description:

Tablets

Treatment:

Drug: fesoterodine fumarate

Placebo

Placebo Comparator group

Description:

Tablets

Treatment:

Drug: placebo

Solifenacin

Active Comparator group

Description:

Tablets

Treatment:

Drug: solifenacin